Investing.com -- Shares of Penumbra (NYSE:PEN) rose by 5% following comments from Piper Sandler analyst Matt O’Brien, who indicated that the medical device company’s Thunderbolt product might ...

Penumbra, Inc. (NYSE:PEN) investors will be delighted, with the company turning in some strong numbers with its latest results. It was overall a positive result, with revenues beating expectations ...

Guidance: Penumbra reaffirms its fiscal year 202 sales guidance of $1.34 billion to $1.36 billion, versus the consensus of $1.35 billion. The company is increasing guidance for the U.S ...

Penumbra Inc. (PEN), a medical devices company with a market capitalization of $10.78 billion, reported robust financial results for the first quarter of 2025, surpassing expectations and sending ...

Penumbra (PEN) came out with quarterly earnings of $0.83 per share, beating the Zacks Consensus Estimate of $0.66 per share. This compares to earnings of $0.41 per share a year ago. These figures ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

ALAMEDA, Calif. (AP) — ALAMEDA, Calif. (AP) — Penumbra Inc. (PEN) on Wednesday reported first-quarter net income of $39.2 million. On a per-share basis, the Alameda, California-based company ...

There are two levels of shadow: Partial lunar eclipse: The moon enters Earth's outer shadow (penumbra) and appears slightly darker. Total lunar eclipse: The moon moves into Earth's darkest shadow ...

Penumbra's shares have surged again on renewed confidence in mechanical thrombectomy growth and a competitor's acquisition, but the current valuation is high at over 7x 2025 revenue estimate ...

Penumbra reported Q4 sales of $315.52 million, up 10.8% Y/Y, beating estimates of $311.55 million. U.S. thrombectomy sales jumped 27.3%, driving global growth of 15.4%. Memorial Day Special ...

Penumbra closed 2024 on a strong note, driven by robust growth in its U.S. thrombectomy business and the successful introduction of new CAVT products. Despite challenges in the China market and ...

Medical device company Penumbra (NYSE:PEN) will be reporting earnings tomorrow afternoon. Here’s what you need to know. Penumbra beat analysts’ revenue expectations by 1.3% last quarter ...